Patents by Inventor Marianna ROWLANDS

Marianna ROWLANDS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING AN INFLAMMATORY OR OBSTRUCTIVE AIRWAY DISEASE USING ANTI-TSLP ANTIBODY
    Publication number: 20230082287
    Abstract: The present disclosure relates to methods, treatment regimens, uses, kits, compositions and medicaments for treating an inflammatory or obstructive airway disease, such as asthma, including severe asthma, or COPD, by employing an anti-TSLP antibody or anti-TSLP antibody fragment.
    Type: Application
    Filed: January 28, 2021
    Publication date: March 16, 2023
    Inventors: Ankur AJMERA, Jürgen DEDERICHS, Sarah Schmidt GRANT, Kristin HENSON, Monish JAIN, Sandro PAGANI, Yinuo PANG, Marianna ROWLANDS
  • PULMONARY HYPERTENSION BIOMARKER
    Publication number: 20220389507
    Abstract: Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension. We have identified CCL21 as anti-remodelling efficacy biomarker for pulmonary hypertension. CCL21 was found to be highly sensitive and specific in discriminating pulmonary hypertension patients from matched controls. CCL21 was upregulated in pulmonary hypertension and down-regulated with treatment with an anti-remodelling agent.
    Type: Application
    Filed: February 17, 2022
    Publication date: December 8, 2022
    Inventors: Marianna ROWLANDS, Clemence Anne Jeanne Marie TESSIER, Paul Andrew WHITTAKER
  • PULMONARY HYPERTENSION BIOMARKER
    Publication number: 20200002768
    Abstract: Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension. We have identified CCL21 as anti-remodelling efficacy biomarker for pulmonary hypertension. CCL21 was found to be highly sensitive and specific in discriminating pulmonary hypertension patients from matched controls. CCL21 was upregulated in pulmonary hypertension and down-regulated with treatment with an anti-remodelling agent.
    Type: Application
    Filed: July 2, 2019
    Publication date: January 2, 2020
    Inventors: Marianna ROWLANDS, Clemence Anne Jeanne Marie TESSIER, Paul Andrew WHITTAKER
  • PULMONARY HYPERTENSION BIOMARKER
    Publication number: 20170088897
    Abstract: Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension. We have identified CCL21 as anti-remodelling efficacy biomarker for pulmonary hypertension. CCL21 was found to be highly sensitive and specific in discriminating pulmonary hypertension patients from matched controls. CCL21 was upregulated in pulmonary hypertension and down-regulated with treatment with an anti-remodelling agent.
    Type: Application
    Filed: May 29, 2015
    Publication date: March 30, 2017
    Applicant: NOVARTIS AG
    Inventors: Marianna ROWLANDS, Clemence Anne Jeanne Marie TESSIER, Paul Andrew WHITTAKER